Pediatric Medication Use in Female Patients
For female pediatric patients, medication selection must account for age-specific pharmacokinetic differences, organ maturity, and FDA-approved pediatric indications rather than simply scaling adult doses. 1
Age Definition and Considerations
- Pediatric care encompasses patients from periconceptional period through gestation, infancy, childhood, adolescence, and young adulthood, with no fixed upper age limit. 2
- Arbitrary age limits should be discouraged; the decision to continue pediatric care should be made by the patient, family, and physician based on individual needs. 2
Critical Dosing Principles
- Pediatric patients require individualized dosing based on age, size, and organ maturity—not simply reduced "small adult" doses. 1
- Many medications lack FDA-approved pediatric indications and dosing guidelines, increasing the risk of dosing errors that can produce serious or fatal complications. 1
- As of 2018,64% of new drug indications deemed relevant to pediatric patients lacked pediatric prescribing information at five years after FDA approval. 3
Medication Safety Framework
- Adult hospitals treating pediatric patients must implement specific pediatric medication safety protocols, including technology optimization, dedicated pediatric pharmacist involvement, and specialized training. 4
- The absence of pediatric dosage forms for many medications substantially increases dosing error potential. 1
- Vascular access considerations differ in pediatric resuscitation: intraosseous or any vascular route is preferable to endotracheal drug administration. 5
Condition-Specific Guidance for Female Pediatric Patients
Hidradenitis Suppurativa (if applicable)
- For adolescent females with HS requiring anti-androgens, spironolactone or combined oral contraceptives are suggested. 6
- For pediatric patients ≥8 years requiring systemic antibiotics, oral doxycycline is recommended. 6
- Adalimumab is FDA-approved for patients ≥12 years (strong recommendation) and suggested for ages 2-11 years for severe/refractory disease. 6, 7
Psoriasis (if applicable)
- Etanercept is approved for pediatric patients >6 years of age at 0.8 mg/kg per week (maximum 50 mg/week). 8
- Ustekinumab is approved for patients ≥12 years, with weight-based dosing: 0.75 mg/kg (<60 kg), 45 mg (60 to <100 kg), or 90 mg (≥100 kg). 8
ADHD (if applicable - Methylphenidate)
- For children ≥6 years, methylphenidate oral solution should be administered 2 times daily before breakfast and lunch, 30-45 minutes before meals. 9
- Contraindicated in patients taking or who stopped MAOIs within 14 days. 9
- Monitor for slowing of growth (height and weight), cardiovascular effects, and psychiatric symptoms during treatment. 9
Critical Pitfalls to Avoid
- Do not assume medication safety or efficacy in pediatric patients based solely on adult data—pharmacokinetic parameters differ substantially. 1
- Do not use arbitrary age cutoffs for transitioning from pediatric to adult care; base decisions on individual patient needs and provider capabilities. 2
- Avoid off-label use without careful consideration, as high rates of non-evidence-based medication use persist in pediatric populations. 3
- In adult hospitals treating pediatric patients, ensure specialized pediatric pharmacy support and technology safeguards are in place. 4